Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has David W. Boulton's publication output changed over time?
ScholarIQpublication output · 1998–2020
Output grew200% over the shown period — from 1 works in 1998 to 3 in 2020.
1
1
1
1
2
1
1
3
19982000200220092013201720182020
What are the most-cited papers on David W. Boulton?
ScholarIQmost cited works
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Mark C. Petrie, Subodh Verma, Kieran F. Docherty, Silvio E. Inzucchi, Inder S. Anand, Jan Bělohlávek, Michael Böhm, Chern‐En Chiang, Vijay Chopra, Rudolf A. de Boer, Akshay S. Desai, Mirta Díez, Jarosław Dróżdż, Andre Dukát, Junbo Ge, Jonathan G. Howlett, Tzvetana Katova, Masafumi Kitakaze, Charlotta Ljungman, Béla Merkely, José Carlos Nicolau, Eileen O’Meara, Pham Nguyễn Vinh, Morten Schou, С. Н. Терещенко, Lars Køber, Mikhail Kosiborod, Anna Maria Langkilde, Felipe A. Martínez, Piotr Ponikowski, Marc S. Sabatine, Mikaela Sjöstrand, Scott D. Solomon, Per Johanson, Peter J. Greasley, David W. Boulton, Olof Bengtsson, Pardeep S. Jhund, John J.V. McMurray
JAMA. 2020542 CitationsOPEN ACCESS
Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis
Karen Melissa Hallow, Gabriel Helmlinger, Peter J. Greasley, John J.V. McMurray, David W. Boulton
Diabetes Obesity and Metabolism. 2017487 CitationsOPEN ACCESS
Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
Bernard J. Komoroski, N. Vachharajani, David W. Boulton, David M. Kornhauser, Margarida Geraldes, L Li, Marc Pfister
S159852663. 2009348 CitationsOPEN ACCESS
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
Ralph A. DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula, Xiaoni Liu, Ying Hong, Marc Pfister, Linda Morrow, Bruce R. Leslie, David W. Boulton, Agatha Ching, Frank LaCreta, Steven C. Griffen
Diabetes Care. 2013289 CitationsOPEN ACCESS
Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
Sreeneeranj Kasichayanula, Xiaoni Liu, Frank LaCreta, Steven C. Griffen, David W. Boulton
S69290020. 2013277 Citations
Related on ScholarIQ
AstraZeneca (South Korea)
Institution
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Paper
Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis
Paper
Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
Paper
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
Paper
Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
Paper